ECL Ecolab
Premium franchise, premium price — margins and growth don't justify 27x revenue.
The story
Ecolab is a premium water, hygiene, and infection prevention franchise with sticky customer relationships and switching costs. Revenue growth is decelerating toward mid-single digits as the post-pandemic normalization completes, while margins have stabilized around 17-18% — below the 19% target I previously assumed. The market prices in a transformation story that the financials don't yet support.
Trimmed Y1 growth from 5.5% to 5% as TTM revenue growth slows and 5y CAGR is only 4.3%. Cut target margin from 19% to 18% — TTM margin is 17.5% and the 18.5% peak looks like a high-water mark, not a sustainable level. Shortened margin convergence from 7 to 5 years since margins are already near target. Sales-to-capital adjusted from 0.95 to 0.94 to match actual TTM. Terminal growth stays at 3.5%, below the 4.94% risk-free rate.
Value drivers
| Revenue growth (Y1) | 5.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 8y |
| Target operating margin | 18.0% |
| Years to target margin | 5 |
| Sales-to-capital | 0.94 |
| Beta | 1.10 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.5% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 11.32B |
| PV of terminal value | 23.13B |
| Equity value | 26.56B |
| ÷ shares → per share | $94.73 |
News
neutral +0.10 · 8 articles
- Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
- Is Ecolab Stock Underperforming the Nasdaq?
- Ecolab (ECL) Up 2.4% Since Last Earnings Report: Can It Continue?
- Bill Gates owns $25 billion in blue-chip S&P 500 stock
- Ecolab Stock: Is Wall Street Bullish or Bearish?
- Ecolab's Projected Commodity Cost Increase in H2 Manageable, RBC Capital Markets Says
- Ecolab's CoolIT Deal Raises AI Upside but Also Debt and Cost Risks
- Is Ecolab Stock Worth Buying as Growth Rises but Debt Risk Builds?
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 17.68B | 5.0% | 17.6% | 2.56B | 895.88M | 1.67B | 1.52B |
| 2 | 18.53B | 4.8% | 17.7% | 2.70B | 900.36M | 1.80B | 1.50B |
| 3 | 19.38B | 4.6% | 17.8% | 2.84B | 901.20M | 1.93B | 1.47B |
| 4 | 20.22B | 4.4% | 17.9% | 2.98B | 898.22M | 2.08B | 1.45B |
| 5 | 21.06B | 4.1% | 18.0% | 3.11B | 891.26M | 2.22B | 1.41B |
| 6 | 21.89B | 3.9% | 18.0% | 3.24B | 880.18M | 2.36B | 1.37B |
| 7 | 22.70B | 3.7% | 18.0% | 3.36B | 864.86M | 2.49B | 1.32B |
| 8 | 23.50B | 3.5% | 18.0% | 3.47B | 845.23M | 2.63B | 1.27B |
Key risks
- Margin compression if input costs or competitive pressure intensifies
- Revenue growth disappoints as industrial end markets slow
- High valuation leaves no room for execution missteps
Catalysts
- Water scarcity megatrend accelerating demand for treatment solutions
- Digital/ IoT service differentiation expanding pricing power
- Operating leverage from cost optimization initiatives